(Q34174307)

31 July 2017

1 reference

title

Advances in iron chelation: an update (English)

1 reference

31 July 2017

Hossein Heli

1

0 references

author name string

Siamak Mirtorabi

series ordinal

2

1 reference

31 July 2017

Khashayar Karimian

series ordinal

3

1 reference

31 July 2017

language of work or name

English

0 references

publication date

30 March 2011

1 reference

Expert Opinion on Therapeutic Patents

31 July 2017

published in

1 reference

31 July 2017

volume

21

1 reference

31 July 2017

issue

6

1 reference

31 July 2017

page(s)

819-856

1 reference

An overview of iron metabolism: molecular and cellular criteria for the selection of iron chelators.

31 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

Proteolytic enzymes of the erythrocytic forms of roden and simian species of malarial plasmodia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

The role of iron chelation in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

Monitoring the efficiency of iron chelation therapy: the potential of nontransferrin-bound iron.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

Non-transferrin-bound iron reaches mitochondria by a chelator-inaccessible mechanism: biological and clinical implications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

Iron metabolism and iron chelation in sickle cell disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

Abnormalities of the large ribosomal subunit protein, Rpl35a, in Diamond-Blackfan anemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

Human lactoferrin: a novel therapeutic with broad spectrum potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

Molecular structure, binding properties and dynamics of lactoferrin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

The effect of lactoferrin on oral bacterial attachment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

The role of antioxidants and iron chelators in the treatment of oxidative stress in thalassemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

Protective hemoglobinopathies and Plasmodium falciparum transmission

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

Malaria and iron: history and review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

An unusually frequent beta-thalassemia mutation in an Iranian Province

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

Results of long-term iron-chelating therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

Long-term therapy with deferiprone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

The universal mechanism for iron translocation to the ferroxidase site in ferritin, which is mediated by the well conserved transit site

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

Release of iron from ferritin requires lysosomal activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

Serum ferritin concentration and iron stores in normal subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

Role of the liver in normal iron metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

Molecular cloning of transferrin receptor 2. A new member of the transferrin receptor-like family

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

Hereditary hemochromatosis: pathogenesis, diagnosis, and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

Physiology of iron transport and the hemochromatosis gene.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

An iron-regulated ferric reductase associated with the absorption of dietary iron

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

The role of Dcytb in iron metabolism: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

Human hephaestin expression is not limited to enterocytes of the gastrointestinal tract but is also found in the antrum, the enteric nervous system, and pancreatic {beta}-cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

A novel mammalian iron-regulated protein involved in intracellular iron metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

The iron-regulatory peptide hepcidin is upregulated in the ischemic and in the remote myocardium after myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

Hepcidin: a putative iron-regulatory hormone relevant to hereditary hemochromatosis and the anemia of chronic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

Hepcidin in beta-thalassemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

Hepcidin and Hfe in iron overload in beta-thalassemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

The iron complex of Dp44mT is redox-active and induces hydroxyl radical formation: an EPR study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

Emerging understanding of the advantage of small molecules such as hydroxypyridinones in the treatment of iron overload

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

Optimization of culture medium to increase the production of desferrioxamine B (Desferal) in Streptomyces pilosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

Transfusional iron overload and chelation therapy with deferoxamine and deferiprone (L1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

Comparison of oral iron chelator L1 and desferrioxamine in iron-loaded patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

Iron chelation studies using desferrioxamine and the potential oral chelator, 1,2-dimethyl-3-hydroxypyrid-4-one, in normal and iron loaded rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

Safety monitoring of cardiac and hepatic systems in beta-thalassemia patients with chelating treatment in Taiwan

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

Myocardial iron loading in patients with thalassemia major on deferoxamine chelation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

Cardiovascular MRI in thalassemia major

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

Causes for hospitalization and death in Iranian patients with β-thalassemia major.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

Chelation therapy in beta-thalassemia: an optimistic update

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

Design of clinically useful iron(III)-selective chelators

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

Combined iron chelation therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

Reduction of body iron stores to normal range levels in thalassaemia by using a deferiprone/deferoxamine combination and their maintenance thereafter by deferiprone monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

Mechanisms for the shuttling of plasma non-transferrin-bound iron (NTBI) onto deferoxamine by deferiprone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

The 18th ICOC Proceedings in Athens, Greece: New breakthrough in thalassemia leading to the complete treatment of iron overload and to hundreds of patients achieving and maintaining normal body iron stores. Ethical questions on chelation therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

Thalassemia as a global health problem: recent progress toward its control in the developing countries

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

The safety and effectiveness of deferiprone in a large-scale, 3-year study in Italian patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

A multi-center safety trial of the oral iron chelator deferiprone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

Deferiprone chelation therapy for thalassemia major

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

The safety, tolerability, and efficacy of a liquid formulation of deferiprone in young children with transfusional iron overload

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

Synthesis and antiviral evaluation of cyclic and acyclic 2-methyl-3-hydroxy-4-pyridinone nucleoside derivatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

Deferasirox (Exjade) for the treatment of iron overload

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

Acquired Proximal Renal Tubular Dysfunction in β-Thalassemia Patients Treated With Deferasirox

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

Deferasirox--current knowledge and future challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

Cost effectiveness of once-daily oral chelation therapy with deferasirox versus infusional deferoxamine in transfusion-dependent thalassaemia patients: US healthcare system perspective.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

Pharmacokinetics, metabolism, and disposition of deferasirox in beta-thalassemic patients with transfusion-dependent iron overload who are at pharmacokinetic steady state

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

Iron chelator research: past, present, and future

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

Design, synthesis, and testing of non-nephrotoxic desazadesferrithiocin polyether analogues.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

Multifunctional antioxidant activity of HBED iron chelator

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

Prostaglandins and leukotrienes: advances in eicosanoid biology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

21 January 2018

Microbial iron compounds

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

Inhibitory mechanisms of heterocyclic carboxaldehyde thiosemicabazones for two forms of human ribonucleotide reductase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

ICL670A: a new synthetic oral chelator: evaluation in hypertransfused rats with selective radioiron probes of hepatocellular and reticuloendothelial iron stores and in iron-loaded rat heart cells in culture

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

Potentiometric, spectrophotometric and calorimetric study on iron(III) and copper(II) complexes with 1,2-dimethyl-3-hydroxy-4-pyridinone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

Potential protection from toxicity by oral iron chelators

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

Iron chelation beyond transfusion iron overload.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

Metals ions and neurodegeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

Iron: a new target for pharmacological intervention in neurodegenerative diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

The transition metals copper and iron in neurodegenerative diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

Metal ion-dependent effects of clioquinol on the fibril growth of an amyloid {beta} peptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

Restoration of nigrostriatal dopamine neurons in post-MPTP treatment by the novel multifunctional brain-permeable iron chelator-monoamine oxidase inhibitor drug, M30.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

Glucosylated Deferiprone and Its Brain Uptake: Implications for Developing Glucosylated Hydroxypyridinone Analogues Intended to Cross the Blood−Brain Barrier

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

Selective iron chelation in Friedreich ataxia: biologic and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

Neuroprotective multifunctional iron chelators: from redox-sensitive process to novel therapeutic opportunities

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

Mitochondrial iron metabolism and its role in neurodegeneration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

The ins and outs of mitochondrial iron-loading: the metabolic defect in Friedreich's ataxia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

Protection against hydrogen peroxide-mediated cytotoxicity in Friedreich's ataxia fibroblasts using novel iron chelators of the 2-pyridylcarboxaldehyde isonicotinoyl hydrazone class.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

Synthesis, characterization, and metal coordinating ability of multifunctional carbohydrate-containing compounds for Alzheimer's therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

Nanoparticle and iron chelators as a potential novel Alzheimer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

Chapter 5 - Development of iron chelator-nanoparticle conjugates as potential therapeutic agents for Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

Iron chelation as a potential therapy for neurodegenerative disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

Combating Alzheimer's disease with multifunctional molecules designed for metal passivation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

Post-hypoxic cellular disintegration in glycine-preserved renal tubules is attenuated by hydroxyl radical scavengers and iron chelators

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

Polyol pathway mediates iron-induced oxidative injury in ischemic-reperfused rat heart

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

The nitrate-nitrite-nitric oxide pathway in physiology and therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

Imidazo[2,1-b]thiazoles and their use as pharmaceuticals: Sanofi-Aventis EP 1 923 062 A1 (equivalent to WO2008058641).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

Nitric oxide donors: chemical activities and biological applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

Chelation of mitochondrial iron prevents seizure-induced mitochondrial dysfunction and neuronal injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

HIF-1alpha dysfunction in diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

Mechanisms of anthracycline cardiac injury: can we identify strategies for cardioprotection?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

The use of dexrazoxane for the prevention of anthracycline extravasation injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

Dexrazoxane prevents doxorubicin-induced long-term cardiotoxicity and protects myocardial mitochondria from genetic and functional lesions in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

Comparison of clinically used and experimental iron chelators for protection against oxidative stress-induced cellular injury.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

Anthracycline toxicity to cardiomyocytes or cancer cells is differently affected by iron chelation with salicylaldehyde isonicotinoyl hydrazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

Study of daunorubicin cardiotoxicity prevention with pyridoxal isonicotinoyl hydrazone in rabbits.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

Cardioprotective effects of a novel iron chelator, pyridoxal 2-chlorobenzoyl hydrazone, in the rabbit model of daunorubicin-induced cardiotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

Deferiprone protects against doxorubicin-induced myocyte cytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

Deferiprone does not protect against chronic anthracycline cardiotoxicity in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

The oral iron chelator ICL670A (deferasirox) does not protect myocytes against doxorubicin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

Anthracycline cardiotoxicity: from bench to bedside

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

Iron chelation with salicylaldehyde isonicotinoyl hydrazone protects against catecholamine autoxidation and cardiotoxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

Aminoglycoside antibiotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

alpha-Tocopherol protective effects on gentamicin ototoxicity: an experimental study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

Morphological evidence of ototoxicity of the iron chelator deferoxamine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

Iron chelators may help prevent photoaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

Synergistic topical photoprotection by a combination of the iron chelator 2-furildioxime and sunscreen

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

Prevention of the photodamage in the hairless mouse dorsal skin by kojic acid as an iron chelator

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

In vivo assembly of the tau-complex of the DNA polymerase III holoenzyme expressed from a five-gene artificial operon. Cleavage of the tau-complex to form a mixed gamma-tau-complex by the OmpT protease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

Effect on ribonucleotide reductase of novel lipophilic iron chelators: the desferri-exochelins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

Design, synthesis, and characterization of novel iron chelators: structure-activity relationships of the 2-benzoylpyridine thiosemicarbazone series and their 3-nitrobenzoyl analogues as potent antitumor agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

Future of toxicology--iron chelators and differing modes of action and toxicity: the changing face of iron chelation therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

A phase II trial of triapine (NSC# 663249) and gemcitabine as second line treatment of advanced non-small cell lung cancer: Eastern Cooperative Oncology Group Study 1503

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

Phase I and pharmacokinetic study of the ribonucleotide reductase inhibitor, 3-aminopyridine-2-carboxaldehyde thiosemicarbazone, administered by 96-hour intravenous continuous infusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

Iron chelators inhibit the growth and induce the apoptosis of Kaposi's sarcoma cells and of their putative endothelial precursors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

Thiosemicarbazones from the old to new: iron chelators that are more than just ribonucleotide reductase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

The evolution of iron chelators for the treatment of iron overload disease and cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

Novel di-2-pyridyl-derived iron chelators with marked and selective antitumor activity: in vitro and in vivo assessment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

Piperidones with activity against Plasmodium falciparum

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

Parasite uptake of desferroxamine: a prerequisite for antimalarial activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

Recent advances in antimalarial drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

Novel aroylhydrazone and thiosemicarbazone iron chelators with anti-malarial activity against chloroquine-resistant and -sensitive parasites

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

Iron chelation therapy for malaria: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

Design, synthesis, and evaluation of novel 2-substituted 3-hydroxypyridin-4-ones: structure-activity investigation of metalloenzyme inhibition by iron chelators

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

The three-dimensional structure of an arachidonic acid 15-lipoxygenase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

Zileuton: clinical implications of 5-Lipoxygenase inhibition in severe airway disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

The 5-lipoxygenase inhibitor, zileuton, suppresses prostaglandin biosynthesis by inhibition of arachidonic acid release in macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

Zileuton, a new efficient and safe systemic anti-acne drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

Viral infection and iron metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

HIV-1 Nef down-regulates the hemochromatosis protein HFE, manipulating cellular iron homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

Human immunodeficiency virus type 1 replication inhibition by the bidentate iron chelators CP502 and CP511 is caused by proliferation inhibition and the onset of apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

Iron chelators ICL670 and 311 inhibit HIV-1 transcription

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

Inhibition of HIV-1 gene expression by Ciclopirox and Deferiprone, drugs that prevent hypusination of eukaryotic initiation factor 5A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

The antifungal drug ciclopirox inhibits deoxyhypusine and proline hydroxylation, endothelial cell growth and angiogenesis in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

Anti-HIV effect of iron chelators: different mechanisms involved

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

Inhibition of human immunodeficiency virus type 1 replication in human mononuclear blood cells by the iron chelators deferoxamine, deferiprone, and bleomycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

The effect of iron overload on in vitro HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

Necrosis of host cells and survival of pathogens following iron overload in an in vitro model of co-infection with human immunodeficiency virus (HIV) and Mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

Iron chelation as therapy for HIV and Mycobacterium tuberculosis co-infection under conditions of iron overload

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

Small coronary vessel angioplasty: outcomes and technical considerations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

Prolyl 4-hydroxylases, key enzymes in the synthesis of collagens and regulation of the response to hypoxia, and their roles as treatment targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

Human deoxyhypusine hydroxylase, an enzyme involved in regulating cell growth, activates O2 with a nonheme diiron center

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

Deoxyhypusine hydroxylase is a Fe(II)-dependent, HEAT-repeat enzyme. Identification of amino acid residues critical for Fe(II) binding and catalysis [corrected].

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

Factor inhibiting hypoxia-inducible factor (FIH) and other asparaginyl hydroxylases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

Molecular cloning, expression, and structural prediction of deoxyhypusine hydroxylase: a HEAT-repeat-containing metalloenzyme

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

Hypoxia-inducible factor prolyl 4-hydroxylase inhibition. A target for neuroprotection in the central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

Prolyl hydroxylase inhibitors increase neoangiogenesis and callus formation following femur fracture in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

Inhibition of prolyl 4-hydroxylase reduces scar hypertrophy in a rabbit model of cutaneous scarring

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

Antiretroviral effects of deoxyhypusyl hydroxylase inhibitors: a hypusine-dependent host cell mechanism for replication of human immunodeficiency virus type 1 (HIV-1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

Specific inhibition of eIF-5A and collagen hydroxylation by a single agent. Antiproliferative and fibrosuppressive effects on smooth muscle cells from human coronary arteries

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

Selective inhibition of factor inhibiting hypoxia-inducible factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

Hinokitiol activates the hypoxia-inducible factor (HIF) pathway through inhibition of HIF hydroxylases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

Desferrioxamine as immunomodulatory agent during microorganism infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

Effect of iron chelation on the in-vitro growth of Leishmania promastigotes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

Identification of a new hexadentate iron chelator capable of restricting the intramacrophagic growth of Mycobacterium avium

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

In vitro time-kill activities of ciprofloxacin alone and in combination with the iron chelator deferasirox against Vibrio vulnificus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

Effects of chelators (deferoxamine, deferiprone and deferasirox) on the growth of Klebsiella pneumoniae and Aeromonas hydrophila isolated from transfusion-dependent thalassemia patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

Leishmania donovani depletes labile iron pool to exploit iron uptake capacity of macrophage for its intracellular growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

Antifungal therapy in invasive fungal infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

21 January 2018

Ciclopirox: an overview.

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

Anti-inflammatory activity of antifungal preparations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

Chelation of intracellular iron with the antifungal agent ciclopirox olamine induces cell death in leukemia and myeloma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

Redox-active metals, oxidative stress, and Alzheimer's disease pathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

Targeting multiple Alzheimer's disease etiologies with multimodal neuroprotective and neurorestorative iron chelators

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

Bifunctional drug derivatives of MAO-B inhibitor rasagiline and iron chelator VK-28 as a more effective approach to treatment of brain ageing and ageing neurodegenerative diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

Propargylamine containing compounds as modulators of proteolytic cleavage of amyloid-beta protein precursor: involvement of MAPK and PKC activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

Site-activated multifunctional chelator with acetylcholinesterase and neuroprotective-neurorestorative moieties for Alzheimer's therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases: in vitro studies on antioxidant activity, prevention of lipid peroxide formation and monoamine oxidase inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

Therapeutic targets and potential of the novel brain- permeable multifunctional iron chelator-monoamine oxidase inhibitor drug, M-30, for the treatment of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

Design, synthesis, and evaluation of novel bifunctional iron-chelators as potential agents for neuroprotection in Alzheimer's, Parkinson's, and other neurodegenerative diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

The novel multifunctional, iron-chelating drugs M30 and HLA20 protect pancreatic beta-cell lines from oxidative stress damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

Preliminary studies of a novel bifunctional metal chelator targeting Alzheimer's amyloidogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

Medicinal inorganic chemistry approaches to passivation and removal of aberrant metal ions in disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

Multifunctional antioxidants for the treatment of age-related diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

Iron Chelators as Potential Therapeutic Agents for Parkinson's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

Up-regulation of hypoxia-inducible factor (HIF)-1α and HIF-target genes in cortical neurons by the novel multifunctional iron chelator anti-Alzheimer drug, M30.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

Multifunctional neuroprotective derivatives of rasagiline as anti-Alzheimer's disease drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

Is drug release necessary for antimicrobial activity of siderophore-drug conjugates? Syntheses and biological studies of the naturally occurring salmycin "Trojan Horse" antibiotics and synthetic desferridanoxamine-antibiotic conjugates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

Siderophores as drug delivery agents: application of the "Trojan Horse" strategy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

Iron metabolism: a promising target for antibacterial strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

New quinolone antibiotics: a survey of the literature from 2005 to 2010.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

Studies and syntheses of siderophores, microbial iron chelators, and analogs as potential drug delivery agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

Microbial iron chelators as drug delivery agents: the rational design and synthesis of siderophore-drug conjugates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

Highly antibacterial active aminoacyl penicillin conjugates with acylated bis-catecholate siderophores based on secondary diamino acids and related compounds

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

Syntheses and studies of multiwarhead siderophore-5-fluorouridine conjugates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

Desketoneoenactin-siderophore conjugates for Candida: evidence of iron transport-dependent species selectivity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

Siderophore uptake in bacteria and the battle for iron with the host; a bird's eye view

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

Albomycin is an effective antibiotic, as exemplified with Yersinia enterocolitica and Streptococcus pneumoniae.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

Siderophore peptide, a new type of post-translationally modified antibacterial peptide with potent activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

Design and synthesis of a novel protected mixed ligand siderophore

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

Chemistry and biology of siderophores

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

Design and synthesis of a siderophore conjugate as a potent PSMA inhibitor and potential diagnostic agent for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

Siderophore-antibiotic conjugates used as trojan horses against Pseudomonas aeruginosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

New synthetic siderophores and their beta-lactam conjugates based on diamino acids and dipeptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

Electrocatalytic oxidation and determination of deferasirox and deferiprone on a nickel oxyhydroxide-modified electrode

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

The effects of deferiprone and deferasirox on the structure and function of beta-thalassemia hemoglobin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

Synthetic and natural iron chelators: therapeutic potential and clinical use

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

The inhibition of factor inhibiting hypoxia-inducible factor (FIH) by β-oxocarboxylic acids

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

Iron transport-mediated drug delivery using mixed-ligand siderophore-β-lactam conjugates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

Iron chelation-afforded cardioprotection against chronic anthracycline cardiotoxicity: A study of salicylaldehyde isonicotinoyl hydrazone (SIH)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.569493

10.1517/13543776.2011.569493

21 January 2018

Identifiers

DOI

1 reference

31 July 2017

1 reference